Philippe Moreau

Philippe Moreau leads the Intergroupe Francophone du Myelome (IFM) and has conducted landmark trials defining optimal induction therapy, transplant eligibility, consolidation, and maintenance in multiple myeloma. He led IFM studies establishing bortezomib-based and lenalidomide-based induction regimens as standards, as well as post-transplant lenalidomide maintenance. His collaborative trials with the Blood and Marrow Transplant Clinical Trials Network and European Myeloma Network have shaped global myeloma treatment guidelines. He has published extensively on smoldering myeloma management and risk-adapted treatment.